Literature DB >> 12648509

Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia.

Jung M Chou1, Chin-Yang Li, Ayalew Tefferi.   

Abstract

Bone marrow specimens from 11 patients with myelofibrosis with myeloid metaplasia (MMM) and seven normal controls were studied immunohistochemically to determine expression of transforming growth factor beta (TGF-beta), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and corresponding receptors. Staining distribution and intensity for TGF-beta, PDGF, VEGF, TGF-beta type II receptor, a receptor for PDGF, and receptors for VEGF and bFGF were similar in patients and controls. Bone marrow from 10 MMM patients showed increased TGF-beta type I receptor (TGF-betaRI) expression in small vessel endothelial cells. Eight patient specimens had bFGF overexpression in megakaryocytes. Increased microvessel density and decreased concentration of bFGF-staining stromal cells accompanied these changes. Microvascular TGF-betaRI upregulation and bFGF overexpression by megakaryocytes may cause bone marrow microenvironmental changes in MMM patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12648509     DOI: 10.1016/s0145-2126(02)00268-0

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  7 in total

1.  Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations.

Authors:  Elie Traer; Nathalie Javidi-Sharifi; Anupriya Agarwal; Jennifer Dunlap; Isabel English; Jacqueline Martinez; Jeffrey W Tyner; Melissa Wong; Brian J Druker
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

2.  Bone marrow expression and plasma concentration of basic fibroblast growth factor in patients with idiopathic thrombocytopenic purpura.

Authors:  Bora Son; Kyeong Seob Shin; Sook Young Bae; Soo-Young Yoon
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

3.  Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis.

Authors:  Stefan O Ciurea; Delwin Merchant; Nadim Mahmud; Takefumi Ishii; Yan Zhao; Wenyang Hu; Edward Bruno; Giovanni Barosi; Mingjiang Xu; Ronald Hoffman
Journal:  Blood       Date:  2007-05-01       Impact factor: 22.113

Review 4.  Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.

Authors:  Abdallah Abou Zahr; Mohamed E Salama; Nicole Carreau; Douglas Tremblay; Srdan Verstovsek; Ruben Mesa; Ronald Hoffman; John Mascarenhas
Journal:  Haematologica       Date:  2016-06       Impact factor: 9.941

5.  Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis.

Authors:  Maria Zingariello; Fabrizio Martelli; Fiorella Ciaffoni; Francesca Masiello; Barbara Ghinassi; Emanuela D'Amore; Margherita Massa; Giovanni Barosi; Laura Sancillo; Xiaochun Li; Judith D Goldberg; Rosa Alba Rana; Anna Rita Migliaccio
Journal:  Blood       Date:  2013-03-05       Impact factor: 22.113

6.  Bone Marrow Soluble Mediator Signatures of Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.

Authors:  Juçara Gastaldi Cominal; Maira da Costa Cacemiro; Maria Gabriela Berzoti-Coelho; Illy Enne Gomes Pereira; Fabiani Gai Frantz; Elizabeth Xisto Souto; Dimas Tadeu Covas; Lorena Lobo de Figueiredo-Pontes; Maria Carolina Oliveira; Kelen Cristina Ribeiro Malmegrim; Fabíola Attié de Castro
Journal:  Front Oncol       Date:  2021-05-18       Impact factor: 6.244

Review 7.  Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms.

Authors:  Gregor Hoermann; Georg Greiner; Peter Valent
Journal:  Mediators Inflamm       Date:  2015-10-12       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.